Opendata, web and dolomites

HEMOSNOW

HEMOSNOW: A revolution in haemostatic technology to stop bleeding in delicate surgery and enhance patient recovery

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 HEMOSNOW project word cloud

Explore the words cloud of the HEMOSNOW project. It provides you a very rough idea of what is the project "HEMOSNOW" about.

feasible    company    vessels    contributes    million    surgery    difficult    limits    minimum    formulation    benefit    medical    techniques    people    postoperative    surgical    longer    procedure    incurs    554    stops    preparation    recovery    tool    250    excessive    resorbable    revenue    surgeon    haemostats    designed    times    transfusion    powder    healthcare    hospitals    time    supplementing    specialises    size    surgeons    post    542    stays    employ    hospital    038    risk    die    commercialisation    formulations    pain    accessible    2005    reduce    bleeding    risks    delayed    normal    rapid    french    day    equip    haemostatic    agents    drainage    biosurgery    errors    generate    lower    6minutes    collagen    always    42    arrest    restricted    spotgrade    suitable    biom    stopping    hemosnow    accumulated    faster    obscured    ready    biotech    stick    mechanism    electrocautery    body    patented    blood    wounds    applicability    stay    room    haemostasis    founded    vision    quantitatively    instruments    hour    operative    lengthy    conventional    patients   

Project "HEMOSNOW" data sheet

The following table provides information about the project.

Coordinator
BIOM'UP SA 

Organization address
address: 8, ALLEE IRENE JOLIOT CURIE
city: SAINT-PRIEST
postcode: 69800
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website https://www.biomup.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2019-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BIOM'UP SA FR (SAINT-PRIEST) coordinator 50˙000.00

Map

 Project objective

Excessive blood loss during surgery is a major concern - 42% of all patients who experience excessive blood loss during surgery die. Excessive bleeding contributes to longer hospital stays and delayed post-operative recovery. This incurs costs for both hospitals and patients with increased operating room time estimated to cost €1,542 - €2,554/hour while increased hospital stay is estimated at €1,038/day. Conventional techniques used to control excessive bleeding such as electrocautery are not always feasible and are often restricted to accessible vessels of a minimum size. This limits their applicability and contributes to postoperative drainage and pain. Haemostatic agents are formulations designed to arrest bleeding by supplementing the normal haemostatic mechanism of the body. Most haemostats currently used by surgeons to control bleeding have lengthy preparation times, are difficult to apply and stick to surgical instruments which limits their suitable application. In response, Biom’up has developed HEMOSNOW, a unique haemostatic powder formulation capable of stopping level 1 & 2 bleeding on the SPOTGRADE scale (developed and patented by Biom’up to quantitatively determine bleeding from surgical wounds). This collagen-based powder is ready to use and stops bleeding within 6minutes. It will equip surgeons with an effective tool for rapid and effective haemostasis, reduce operational procedure time and reduce the risk of surgical errors which occur when the surgeon’s vision is obscured by excessive blood. Patients benefit through lower healthcare costs, faster recovery and lower risks associated with blood transfusion. Biom’up is a French biotech company founded in 2005 which specialises in collagen-based resorbable medical devices for biosurgery. This project is expected to generate an accumulated revenue of €5 million in 5 years post commercialisation and employ 250 people.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HEMOSNOW" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HEMOSNOW" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More  

VACTEC (2019)

VACTEC_Responsive corrosion inhibiting Vacuum Technology-based fire protection system

Read More  

Savesight (2020)

Contact lens embedded sensor for ocular hypertension and glaucoma monitoring

Read More